Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine

Headache

Volumn 38, Issue 10, 1998, Pages 737-747

  Goldstein, Jerome ^a   Ryan, Robert ^b   Jiang, Kaihong ^c   Getson, Albert ^c   Norman, Barbara ^c   Block, Gilbert A ^c   Lines, Christopher ^c  

^a S Francisco (Calif) Headache Clin   (United States)

^b Ryan Headache Center   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Migraine; Rizatriptan; Sumatriptan

Indexed keywords

PLACEBO; RIZATRIPTAN; SUMATRIPTAN;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THORAX PAIN; VERTIGO; XEROSTOMIA;

EID: 0032423808     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3810737.x     Document Type: Article

References (21)

1. Teall JH, Block GA, Smith E, Jiang K, Reines SA. Double-blind study of rizatriptan (MK-0462) in acute migraine and migraine recurrence. Headache. 1997;37:334. Abstract.
2. Kramer MS, Matzura-Wolfe D, Getson A, Polis A, Reines SA. Placebo-controlled, double-blind study of rizatriptan in multiple attacks of acute migraine. Headache. 1997;37:318. Abstract.
3. Visser WH, Teall JH, Malbecq W, Block GA, Reines SA. Early onset of action of rizatriptan versus sumatriptan in the acute treatment of migraine. Headache. 1997;37:334-335. Abstract.
4. Lines C, Visser WH, Vandormael K, Reines SA. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache. 1997;37:319-320. Abstract.
5. Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother. 1994;5:295-310.
6. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. 1995;45(suppl 7):S5-S9.
7. Pfaffenrath V. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, 100 mg) in the acute treatment of migraine: defining the optimum dose of oral sumatriptan. Cephalalgia. 1997;17:420. Abstract.
8. Chustecka Z. All Change in the Migraine Market? Scrip Reports. Richmond, Va: PJB Publications; Surrey. 40-42.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
10. Hartmaier SL, Santanello NC, Epstein RS, Silberstein SD. Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache. 1995;35:320-329.
11. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. Validation of a new quality of life questionnaire for acute migraine headache. Headache. 1995; 35:330-337.
12. Kalbfleish JD, Prentice RL. Marginal likelihood based on Cox's regression life models. Biometrika. 1973;60:267-268.
13. Prentice RL, Gloeckler LA. Regression analysis of grouped survival data with application to breast cancer data. Biometrics. 1978;34:57-67.
14. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
15. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079-1087.
16. Collet D. Modelling Survival Data in Medical Research. London: Chapman and Hall; 1994:24-27.
17. Hochberg Y. A sharper Bonferonni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
18. 1D agonist. Br J Clin Pharmacol. 1997;43:49-54.
19. Sumatriptan Product Information. Physicians' Desk Reference. 52nd ed. Oradell, NJ: Medical Economics Company Inc; 1998:1037.
20. Gobel H, Petersen-Braun M, Heinze A. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. New York: Lippincott-Raven; 1997:93-97.
21. Llewelyn JG, Findley LJ, Gross ML. Migraine symptoms: which cause the most distress? In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. New York: Lippincott - Raven; 1997:153-156.